ORLANDO, Fla., Nov. 2, 2007 (PRIME NEWSWIRE) -- RedChip Companies, Inc. announced that James S. Kuo, M.D., M.B.A., Chairman and Chief Executive Officer of Duska Therapeutics, Inc., was featured in an exclusive RedChip Radio(tm) interview this week. The interview included discussions on the Company's strategic position in the booming pharmaceutical industry, their flagship products that use the energy molecule adenosine triphosphate (ATP), as well as short and long-term objectives for the Company.
RedChip Radio(tm) is a radio news forum that addresses general market and small-cap news and interviews CEOs and executives of prominent small-cap companies.
To hear the interview in its entirety, visit:
http://www.redchip.com/visibility/investor.asp?symbol=dska&daily=20071026&from=news11022007
About Duska Therapeutics, Inc.
Duska Therapeutics, Inc., based in Bala Cynwyd, Pennsylvania, develops new medicines to treat cardiovascular diseases by modulating the P2 receptor in the heart and lungs. In addition to ATPace(tm) (adenosine triphosphate injection) for the treatment and diagnosis of certain cardiac arrhythmias, Duska has drug development programs targeting chronic obstructive pulmonary disorders and cough, male infertility and mitigating the toxic effects of radiation exposure. For more information, visit Duska's website: www.duskatherapeutics.com.
About RedChip Companies, Inc.
RedChip Companies is an international small-cap research and financial public relations firm with offices in Beijing and Orlando and affiliates in New York and San Diego. RedChip delivers measurable results for its clients through its extensive international market expertise as well as its comprehensive platform of products: RedChip Research(tm), Traditional Investor Relations, Digital Investor Relations, Institutional and Retail Conferences held throughout the United States, and RedChip Radio(tm). To learn more about RedChip's products and services please visit: http://www.redchip.com/visibility/services.asp.
"Discovering Tomorrow's Blue Chips Today" (tm)
DISCLOSURE
Any opinions expressed herein are subject to change. Duska Therapeutics is a client of the RedChip Companies, Inc. and has contracted the RedChip Companies to increase investor awareness of DSKA to the small-cap equity community. These services may include investor conferences and digital print distribution of DSKA investor related materials. In the purview of Section 17(b) of the Securities Act of 1933 and in the interest of full disclosure, we call the reader's attention to the fact that RedChip Companies, Inc. is an investor relations firm hired by the Company and receives a monthly fee of $6,000 and receives 30,000 shares of common stock under Rule 144 stock for investor relations services.